ASH

News
blood_cells1 1024x576

ASH roundup: late breakers take the stage

The final day of the ASH congress always includes a session on late-breaking studies, and this year was no exception, with presentations on Novartis' iptacopan in paroxysmal nocturnal haemo

News
Argenx_image

ASH: Argenx cues up a second use for efgartigimod

Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – for primary immune thrombocytopenia (ITP) – thanks to new data reported a